Home › Funds › GLAZER CAPITAL, LLC › DMII
GLAZER CAPITAL, LLC position in DMII
DRUGS MADE IN AMERICA ACQUISITION II CORP · Financials
GLAZER CAPITAL, LLC reported holding 2,343,278 shares of DMII (DRUGS MADE IN AMERICA ACQUISITION II CORP) in its Q2 2026 13F filing — a position valued at US$23.6M, representing 0.70% of its reported portfolio and ranking #21 among its reported holdings. GLAZER CAPITAL, LLC has disclosed DMII holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How GLAZER CAPITAL, LLC's DMII position evolved
GLAZER CAPITAL, LLC first disclosed a stake in DMII in Q4 2025 at 2,349,899 shares (US$23.3M). The position peaked in Q2 2026 at 2,343,278 shares, worth US$23.6M. Across 3 filings, GLAZER CAPITAL, LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 2,343,278 shares valued at US$23.6M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 2.35M | $23.26M | New |
| Q1 2026 | 2.35M | $23.43M | Hold |
| Q2 2026 | 2.34M | $23.57M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DMII and 13F data
DMII (DRUGS MADE IN AMERICA ACQUISITION II CORP) is a Financials company. 70 other funds we track also report a position in DMII — the largest reported positions include Karpus Management, Inc. (US$28.0M), Magnetar Financial LLC (US$27.2M), MMCAP International Inc. SPC (US$27.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DMII
- Karpus Management, Inc. 2.79M sh · $28.05M · Q2 2026
- Magnetar Financial LLC 2.70M sh · $27.16M · Q2 2026
- MMCAP International Inc. SPC 2.70M sh · $27.16M · Q2 2026
- HIGHBRIDGE CAPITAL MANAGEMENT LLC 2.24M sh · $22.57M · Q2 2026
- WOLVERINE ASSET MANAGEMENT LLC 1.86M sh · $18.66M · Q2 2026
- Crossingbridge Advisors, LLC 1.10M sh · $11.07M · Q2 2026
- First Trust Capital Management L.P. 1.07M sh · $10.74M · Q2 2026
- Mercuria Capital Strategies, LLC 750.00K sh · $7.54M · Q2 2026
- HEIGHTS CAPITAL MANAGEMENT, INC 519.40K sh · $5.23M · Q2 2026
- TIG Advisors, LLC 500.00K sh · $5.03M · Q2 2026
- Wealthspring Capital LLC 400.44K sh · $4.03M · Q2 2026
- Logan Stone Capital, LLC 381.69K sh · $3.84M · Q2 2026
More on GLAZER CAPITAL, LLC
FAQ
How long has GLAZER CAPITAL, LLC held DMII?
GLAZER CAPITAL, LLC has disclosed DMII holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is GLAZER CAPITAL, LLC's current position in DMII?
As of Q2 2026, GLAZER CAPITAL, LLC holds 2.34M shares of DMII (DRUGS MADE IN AMERICA ACQUISITION II CORP), valued at $23.57M, representing 0.70% of its reported portfolio and ranking #21.
Has GLAZER CAPITAL, LLC been buying or selling DMII?
In the latest 13F filing (Q2 2026), GLAZER CAPITAL, LLC held unchanged its position in DMII. The position peaked in Q2 2026 at 2.34M shares.
Which other funds hold DMII?
Other major institutional holders of DMII include Karpus Management, Inc., Magnetar Financial LLC, MMCAP International Inc. SPC, among 70 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.